nach oben

Drugs

Erschienen in:

01.01.2006 | Leading Article

Role of Toll-Like Receptors in Infection and Immunity

Clinical Implications

verfasst von: Dr Patricia Cristofaro, Steven M. Opal

Erschienen in: Drugs | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

The remarkable discovery of the Toll-like receptors (TLRs) over the past 5 years has opened up an entirely new era in the understanding of the molecular events that initiate the inflammatory response. These type 1 transmembrane receptors are expressed on a large number of immune cells as well as epithelial cells and play an essential role in the activation of the innate immune response to microbial pathogens. They impact on adaptive immune reactions and contribute to the initiation and maintenance of the inflammatory response to a multitude of potential microbial pathogens through recognition of pathogen-associated molecular patterns. TLRs also interact with a variety of endogenous human ligands and influence the activity of a wide range of tissues and cell processes. Among the common and important processes in which TLRs play a role are asthma, acute respiratory distress syndrome, cardiac ischaemia, coronary artery disease, ventricular remodelling, vascular collapse, inflammatory bowel disease, acute tubular necrosis, psoriasis, rheumatoid arthritis, pre-term birth, fertility, cancer angiogenesis and transplant rejection. From this strikingly diverse list, many important opportunities for disease modification through TLR manipulation can be imagined. Their role as potential targets for therapeutic intervention is just beginning to be appreciated, and the current status of these treatment strategies is reviewed in this article.

Redecke V, Hacker H, Datta SK, et al. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol 2004 Mar 1; 172(5): 2739–43PubMed

Cruz R, Maldonado B, Cuevas U, et al. Toll-like receptors: dysregulation in vivo in patients with acute respiratory distress syndrome. Rev Allerg Mex 2004 Nov–Dec; 51(6): 210–7

Becker S, Fenton MJ, Soukup JM. Involvement of microbial components and Toll-like receptors 2 and 4 in cytokine responses to air pollution particles. Am J Respir Cell Mol Biol 2002 Nov; 27(5): 611–8PubMed

Dybdahl B, Wahba A, Lien E, et al. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through Toll-like receptor-4. Circulation 2002 Feb 12; 105(6): 685–90PubMedCrossRef

Laberge M, Moore K, Freeman M. Arthrosclerosis and innate immune signaling. Ann Med 2005; 37: 130–40PubMedCrossRef

Shishido T, Nozaki N, Yamaguchi S, et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003 Dec 9; 108(23): 2905–10PubMedCrossRef

Nemoto S, Vallejo JG, Knuefermann P, et al. Escherichia coli LPS-induced LV dysfunction: role of Toll-like receptor-4 in the adult heart. Am J Physiol Heart Circ Physiol 2002 Jun; 282(6): H2316–2323PubMed

Lakatos P, Lakatos L, Szalay F, et al. Toll-like receptor 4 and NOD2/CARD 15 mutations in Hungarian patients with Crohn’s disease: phenotype-genotype correlations. World J Gastroenterol 2005 Mar 14; 11(10): 1489–95PubMed

Franchimont D, Vermeire S, El Housni H, et al. Deficient hostbacteria interactions in inflammatory bowel disease? The Toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut 2004 Jul; 53(7): 987–92PubMedCrossRef

10.

Seki E, Tsutsui H, Iimuro Y, et al. Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology 2005 Mar; 41(3): 443–50PubMedCrossRef

11.

Gong Z, Liu C, Wu C, et al. Synthesis of Toll-like receptor 4 in Kupffer cells and its role in alcohol-induced liver disease. Chin Med J (Engl) 2003 Feb; 116(2): 297–300

12.

Kim BS, Lim SW, Li C, et al. Ischemia-reperfusion injury activates innate immunity in rat kidneys. Transplantation 2005 May 27; 79(10): 1370–7PubMedCrossRef

13.

Baker B, Ovigne J, Powles A, et al. Normal keratinocytes express Toll-like receptors (TLRs) 1,2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 2003 Apr; 148(4): 670–9PubMedCrossRef

14.

Pierer M, Rethage J, Seibl R, et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004 Jan 13; 172(2): 1256–65PubMed

15.

Kikuchi T, Matsuguchi T, Tsuboi N, et al. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. J Immunol 2001 Mar 1; 166(5): 3574–9PubMed

16.

Elovitz M, Wang Z, Chien E, et al. A new model for inflammation-induced preterm birth: the role of platelet-activating factor and Toll-like receptor-4. Am J Pathol 2003 Nov; 163(5): 2103–11PubMedCrossRef

17.

Fazeli A, Bruce C, Anumba DO. Characterization of Toll-like receptors in the female reproductive tract in humans. Hum Reprod 2005 May; 20(5): 1372–8PubMedCrossRef

18.

Pinhal-Enfield G, Ramanathan M, Hasko G, et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosoine A(2A) receptors. Am J Pathol 2003 Aug; 163(2): 711–21PubMedCrossRef

19.

Goldstein D, Tesar B, Akira S, et al. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. Am J Transplant 2005 May; 5(5): 969–75CrossRef

20.

Tesar B, Zhang J, Li Q, et al. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a Toll-like receptor signal adaptor protein. Am J Transplant 2004 Sep; 4(9): 1429–39PubMedCrossRef

21.

Palmer S, Burch L, Davis D, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003 Sep 15; 168(6): 628–32PubMedCrossRef

22.

Karpala A, Doran T, Bean A. Immune responses to dsRNA: implications for gene silencing technologies. Immunol Cell Biol 2005; 83: 211–6PubMedCrossRef

23.

Stein D, Roth S, Vogelsang E, et al. The polarity of the dorsoventral axis in the Drosophila embryo is defined by an extracellular signal. Cell 1991; 65: 725–35PubMedCrossRef

24.

Hoffman JA, Reichhart JM. Drosophila immunity. Trends Cell Biol 1997; 7: 309–16CrossRef

25.

Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197–216PubMedCrossRef

26.

Hoffman JA, Kafatos FC, Janeway CA, et al. Phylogenetic perspectives in innate immunity. Science 1999; 284: 1313–7CrossRef

27.

Means TK, Golenbock DT, Fenton MJ. The biology of Toll-like receptors. Cytokine Growth Factor Rev 2000; 11: 219–32PubMedCrossRef

28.

Whitham S, Dinesh-Kumar SP, Choi D, et al. The product of the tobacco mosaic virus resistance gene N: similarity to Toll and the interleukin-1 receptor. Cell 1994; 78: 1101–15PubMedCrossRef

29.

Opal SM, Huber CE. Bench-to-bedside review: Toll-like receptors and their role in septic shock. Crit Care 2002; 6: 125–36PubMedCrossRef

30.

Bowie A, O’Neill L. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 2000; 67: 508–14PubMed

31.

Zhang D, Zhang G, Hayden MS, et al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004; 303: 1522–6PubMedCrossRef

32.

Du X, Poltorak A, Wei Y, et al. Three novel mammalian Toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw 2000 Sep; 11(3): 362–71PubMed

33.

Bieback K, Lien E, Klagge IM, et al. Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling. J Virol 2002; 76: 8729–36PubMedCrossRef

34.

Compton T, Kurt-Jones EA, Boehme KW, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003; 77: 4588–96PubMedCrossRef

35.

Cristofaro P, Opal S. The human Toll-like receptors as a therapeutic target. Expert Opin Ther Targets 2003; 7: 603–12PubMedCrossRef

36.

Weiss DS, Raupach B, Takeda K, et al. Toll-like receptors are temporarily involved in host defense. J Immunol 2004; 172: 4463–9PubMed

37.

Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol 2005; 174: 4453–60PubMed

38.

Cognasse F, Hamzeh H, Chavarin P, et al. Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol 2005; 83(2): 196–8PubMedCrossRef

39.

Lancaster GI, Khan Q, Drysdale P, et al. The physiological regulation of Toll-like receptor expression and function in humans. J Physiol 2005; 563 (Pt 3): 945–55PubMedCrossRef

40.

Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004; 4: 499–511PubMedCrossRef

41.

Kawai T, Akira S. Toll-like receptor downstream signaling. Arthritis Res Ther 2005; 7: 12–9PubMedCrossRef

42.

Yauch LE, Mansour MK, Sholham S, et al. Involvement of CD14, Toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. Infect Immun 2004; 72: 5373–83PubMedCrossRef

43.

Hoebe K, Georgel P, Rutschmann S, et al. CD36 is a sensor of diacylglycerides. Nature 2005 Feb 3; 433: 523–7PubMedCrossRef

44.

Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Res Immunol 2004; 4: 512–20CrossRef

45.

Liew F, Xu D, Brint E, et al. Negative regulation of Toll-like receptor-mediated immune responses. Nature reviews: immunology. 2005 Jun; 5: 446–58PubMedCrossRef

46.

LeBouder E, Rey-Nores J, Rushmere NK, et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003; 171: 6680–9PubMed

47.

Netea MG, Sutmuller R, Herman C, et al. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 2004; 172: 3712–8PubMed

48.

Fitzgerald KA, Rowe DC, Barnes BJ, et al. LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the Toll adapters TRAM and TRIF. J Exp Med 2003; 198: 1043–55PubMedCrossRef

49.

Wang T, Town T, Alexopoulou L, et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004; 10: 1366–73PubMedCrossRef

50.

Ashkar AA, Yao X-D, Gill N, et al. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis 2004; 190: 1841–9PubMedCrossRef

51.

Takeda K. Evolution and integration of innate immune recognition systems: the Toll-like receptors. J Endotoxin Res 2005 Feb; 11(1): 51–5PubMed

52.

Bjorlbacka H, Fitzgerald K, Huet F, et al. The induction of macrophage gene expression by LPS predominantly utilizes MyD88-independent signaling cascades. Physiol Genomics 2004 Nov 17; 19(3): 319–30CrossRef

53.

Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 1998; 282: 2085–8PubMedCrossRef

54.

Watari M, Watari H, Nachamkin I, et al. Lipopolysaccharide induces expression of genes encoding pro-inflammatory cytokines and the elastin-degrading enzyme, cathepsin S, in human cervical smooth-muscle cells. J Soc Gynecol Investig 2000 May–Jun; 7(3): 190–8PubMedCrossRef

55.

Ameziane N, Beillat T, Verpillat P, et al. Association of the Toll-like receptor gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23: 61–4CrossRef

56.

Methe H, Kim J, Kofier S, et al. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005 Apr 28; 25(7): 1439–45PubMedCrossRef

57.

Hawn T, Verbon A, Janer M, et al. Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires’ disease. PNAS 2005 Febl5; 102(7): 2487–9PubMedCrossRef

58.

Palmer S, Burch L, Trindade A, et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 2005 Apr; 171(7): 780–5PubMedCrossRef

59.

Viriyakosol S, Tobias PS, Kitchens RL, et al. MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 2001; 276: 38044–51PubMed

60.

Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 is an adapter protein in the hToll/IL-1 receptor signaling pathways. Mol Cell 1998; 2: 253–8PubMedCrossRef

61.

Kawai T, Takeuchi O, Fujita T, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001; 167: 5887–94PubMed

62.

Lynn M, Rossignol DR, Wheeler J, et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003; 187: 631–9PubMedCrossRef

63.

Savov J, Brass D, Lawson B, et al. Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide (LPS). Am J Physiol Lung Cell Mol Physiol 2005 Aug; 289(2): L329–337PubMedCrossRef

64.

Wami K, Matsuguchi T, Masada A, et al. Cutting edge: naturally occurring soluble form of mouse Toll like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2001; 165: 6682–6

65.

Opal S, Palardy J, Parejo N, et al. Effect of anti-CD14 monoclonal antibody on clearance of Escherichiacolibacteremia and endotoxemia. Crit Care Med 2003; 31: 929–32PubMedCrossRef

66.

Sha T, Li M, Sunamoto M, et al. A novel cytokine production inhibitor, TAK-242, prevents LPS-induced cytokine production and lethality in mice [abstract]. Crit Care Med 2004; 32 Suppl.: 467CrossRef

67.

Zanotti-Cavazzoni SL, Golfarb RD, Dellinger RP. A cytokine production inhibitor (TAK-242) improves cardiovascular performance, inhibits cytokine release and increases survival in a porcine model of gram-negative sepsis [abstract]. Crit Care Med 2004; 32 Suppl.: 59

68.

Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 420: 1099–103CrossRef

69.

Ramos H, Rumbo M, Sirard J, et al. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. Trends Microbiol 2004 Nov; 12(11): 509–16PubMedCrossRef

70.

Dunstan S, Hawn T, Hue N, et al. Host susceptibility and clinical outcomes in Toll-like receptor 5-deficient patients with typhoid fever in Vietnam. J Infect Dis 2005 Apr 1; 191(7): 1068–71PubMedCrossRef

71.

Smith M, Mitchell A, Li G, et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacterpylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem 2003 Aug 29; 278(35): 32552–60PubMedCrossRef

72.

Adamo R, Sokol S, Soong G, et al. Pseudomonasaeruginosa flagella activate airway epithelial cells through asialoGMl and Toll-like receptor 2 as well as Toll-like receptor 5. Am J Respir Cell Mol Biol 2004 May; 30(5): 627–34PubMedCrossRef

73.

Heil F, Hemmi H, Hochrein H, et al. Specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004; 303: 1526–9PubMedCrossRef

74.

Koido S, Kashiwaba M, Chen D, et al. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000; 165: 5713–9PubMed

75.

Kreig AM. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1999; 1489: 107–16CrossRef

76.

Sparwasser T, Miethke T, Lipford G, et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factora-mediated shock. Eur J Immunol 1997; 27: 1671–4PubMedCrossRef

77.

Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via specific CpG motif recognition. Proc Natl Acad Sci U S A 2001; 98: 9237–42PubMedCrossRef

78.

Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740–4PubMedCrossRef

79.

Rifkin I, Leadbetter E, Busconi L, et al. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005 Apr; 204: 27–42PubMedCrossRef

80.

Rutz M, Metzger J, Geliert T, et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 2004 Sep; 34(9): 2541–50PubMedCrossRef

81.

Pasare C, Medzhitov R. Toll-pathway dependent blockade of CD4+CD25+ T cells-mediated suppression by dendritic cells. Science 2003 Feb 14; 299(5609): 1033–6PubMedCrossRef

82.

Gangloff S and Guenounou M. Toll-like receptors and immune response in allergic disease. Clin Rev Allergy Immunol 2004 Apr; 26(2): 115–25PubMedCrossRef

83.

Gao JJ, Xue Q, Papasian CJ, et al. Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-α through a post-transcriptional mechanism. J Immunol 2001; 166: 6855–60PubMed

84.

Halperin S, Van Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003; 21: 2461–7PubMedCrossRef

85.

Weighardt H, Feterowski C, Veit M, et al. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol 2000; 165: 4537–43PubMed

86.

Sun J, Walsah M, Villarino A, et al. TLR ligands can activate dendritic cells to provide a MyD88-dependent negative signal for Th2 cell development. J Immunol 2005 Jan 15; 174(2): 742–51PubMed

87.

Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed on B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD 88. J Immunol 2005; 174: 2942–60PubMed

88.

Lazarus R, Raby BA, Lange C, et al. Toll-like receptor 10 genetic variation is associated with asthma in two independent samples. Am J Respir Crit Care Med 2004; 170: 594–600PubMedCrossRef

89.

Yarovinsky F, Zhang D, Anderson J, et al. TLR 11 activation of dendritic cells by a protozoan profiling-like protein. Science 2005 Jun 10; 308: 1626–9PubMedCrossRef

90.

Opitz B, Püschel A, Schmeck B, et al. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem 2004; 279: 36426–32PubMedCrossRef

91.

Uehara A, Yang S, Fujimoto Y, et al. Muramyl dipeptide and diaminopimelic acid-containing desmuramyl peptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cellular Microbiol 2005; 7(1): 53–61CrossRef

92.

Boneca IG. The role of peptidoglycan in pathogenesis. Curr Opin Microbiol 2005; 8: 46–53PubMedCrossRef

93.

Hollenbach E, Vieth M, Roessner A, et al. Inhibition of RICK/ nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem 2005; 280(15): 14981-8PubMedCrossRef

Titel: Role of Toll-Like Receptors in Infection and Immunity
Clinical Implications
verfasst von: Dr Patricia Cristofaro
Steven M. Opal
Publikationsdatum: 01.01.2006
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 1/2006
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200666010-00002

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2006

Premixed Insulin Analogues for the Treatment of Diabetes Mellitus

Optimising Dosing Strategies of Antibacterials Utilising Pharmacodynamic Principles

Pioglitazone

Anagrelide

Telmisartan